Testing HS-20093 combinations for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (HS-20093) for people with advanced colorectal cancer that has spread or cannot be removed by surgery. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced colorectal cancer that has spread or cannot be removed.
- You must have at least one tumor that can be measured on scans.
- You must be able to take care of yourself (ECOG performance status 0 or 1).
- You can not have had certain prior cancer treatments within specific timeframes.
- You must not be pregnant and must use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
This study tests a combination of several cancer drugs (irinotecan, capecitabine, bevacizumab, and camrelizumab) in people with metastatic colorectal cancer who have already tried at least one prior treatment. The goal is to see if these drugs work better together for patients who don't have certain genetic features.
This trial tests a new combination treatment called HS-20089 for people with advanced solid tumors. The goal is to see if it is safe and how well it works against cancer that has not responded to other treatments.
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
This trial tests a new drug called SSGJ-707 for people with colorectal cancer that has spread. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug (HS-10370) in combination with other cancer treatments for people with advanced solid tumors that have a specific genetic change (KRAS G12C). It's for patients who have tried standard options without success.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.